The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review
Open Access
- 25 October 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6742
Abstract
This study focuses on the use of thiopurines for treating inflammatory bowel diseases (IBD). These drugs undergo enzymatic changes within the body, resulting in active and inactive metabolites that influence their therapeutic effects. The research examines the role of genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) in predicting the therapeutic response and adverse effects of thiopurine treatment. The TPMT genotype variations impact the individual responses to thiopurines. Patients with reduced TPMT activity are more susceptible to adverse reactions (AEs), such leukopenia, hepatotoxicity, pancreatitis, and nausea, which are common adverse effects of thiopurine therapy. The therapeutic monitoring of the metabolites 6-thioguanine nucleotides (6-TGN) and 6-methyl mercaptopurine (6-MMP) is proposed to optimize treatment and minimize AEs. Patients with higher 6-TGN levels tend to have better clinical responses, while elevated 6-MMP levels are linked to hepatotoxicity. Genotyping for TPMT before or during treatment initiation is suggested to tailor dosing strategies and enhance treatment efficacy while reducing the risk of myelosuppression. In conclusion, this study highlights the importance of considering genetic variations and metabolite levels in optimizing thiopurine therapy for IBD patients, focusing on balance therapeutic efficacy with the prevention of adverse effects and contributing to personalized treatment and better patient outcomes.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-03823-17)
- Coordination for the Improvement of Higher Education Personnel (CAPES) (APQ-03823-17)
This publication has 41 references indexed in Scilit:
- ThiopurineS-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patientsJournal of Clinical Pharmacy and Therapeutics, 2010
- Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2008
- Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-FoldClinical Gastroenterology and Hepatology, 2008
- Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacyAlimentary Pharmacology & Therapeutics, 2007
- Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2007
- No Induction of Thiopurine Methyltransferase During Thiopurine Treatment in Inflammatory Bowel DiseaseNucleosides, Nucleotides & Nucleic Acids, 2006
- Inosine Triphosphate Pyrophosphatase and Thiopurine S-Methyltransferase Genotypes Relationship to Azathioprine-Induced MyelosuppressionClinical Gastroenterology and Hepatology, 2006
- TPMT genotype and the use of thiopurines in paediatric inflammatory bowel diseaseDigestive and Liver Disease, 2005
- Thiopurine S‐methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2003
- Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitisJournal of Gastroenterology, 2003